Michael Shi is an accomplished inventor based in East Hanover, NJ (US). He has made significant strides in the field of cancer treatment, particularly focusing on hepatocellular cancer (HCC). His work has the potential to impact the lives of many patients suffering from this challenging disease.

Latest Patents

Michael Shi holds a patent for an organic compound designed for the treatment of hepatocellular cancer (HCC). The patent details a method of treating HCC using 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one or a pharmaceutically acceptable salt or a tautomer thereof, or a hydrate or a solvate. This innovative approach showcases his dedication to advancing medical science.

Career Highlights

Michael Shi is currently employed at Novartis AG, a leading global healthcare company. His role at Novartis allows him to collaborate with other experts in the field and contribute to groundbreaking research and development in pharmaceuticals.

Collaborations

Some of Michael's notable coworkers include Diana Graus Porta and Herbert Schmid. Their collective expertise enhances the innovative environment at Novartis AG, fostering advancements in cancer treatment.

Conclusion

Michael Shi's contributions to the field of cancer treatment through his patent and work at Novartis AG highlight his commitment to improving patient outcomes. His innovative spirit and collaboration with talented colleagues position him as a key figure in the ongoing fight against hepatocellular cancer.

Profile summary based on public USPTO records.